Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ORMP Oramed Pharmaceuticals

Post-Mkt 08-17 16:21:53 EDT

4.57

+0.09

+2.01%

盘后4.57

+0.000.00%

16:15 EDT

High4.60	Low4.44	Vol223.68K
Open4.53	D1 Closing4.48	Amplitude3.57%
Mkt Cap190.10M	Tradable Cap145.20M	Total Shares41.60M
T/O1.01M	T/O Rate0.70%	Tradable Shares31.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ORMP","market":"US","secType":"STK","nameCN":"Oramed Pharmaceuticals","latestPrice":4.57,"timestamp":1786996800000,"preClose":4.48,"halted":0,"volume":223683,"hourTrading":{"tag":"盘后","latestPrice":4.57,"preClose":4.57,"latestTime":"16:15 EDT","volume":764,"amount":3491.48,"timestamp":1786997708901,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02008928571428568,"floatShares":31771900,"shares":41597400,"eps":4.147742,"marketStatus":"Post-Mkt","change":0.09,"latestTime":"08-17 16:21:53 EDT","open":4.53,"high":4.6,"low":4.44,"amount":1009569.5995752,"amplitude":0.035714,"askPrice":4.73,"askSize":88,"bidPrice":4.53,"bidSize":50,"shortable":3,"etf":0,"ttmEps":4.147742,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787011200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":4.48,"dividendRate":0.054726,"preHourTrading":{"tag":"盘前","latestPrice":4.48,"preClose":4.48,"latestTime":"09:27 EDT","volume":2417,"amount":10824.8453262,"timestamp":1786973272794,"change":0,"changeRate":0,"amplitude":0.051406},"postHourTrading":{"tag":"盘后","latestPrice":4.57,"preClose":4.57,"latestTime":"16:15 EDT","volume":764,"amount":3491.48,"timestamp":1786997708901,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.392229,"impliedVol":1.6152,"impliedVolPercentile":0.8367},"requestUrl":"/m/hq/s/ORMP","defaultTab":"news","newsList":[{"id":"2660482791","title":"Nano Dimension Appoints Oramed CEO Nadav Kidron to Board to Chair Strategy, Capital Allocation Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2660482791","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660482791?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:02","pubTimestamp":1786968148,"startTime":"0","endTime":"0","summary":"Nano Dimension appoints Oramed CEO Nadav Kidron to board to chair strategy, capital allocation committeeNano Dimension appointed Oramed Pharmaceuticals CEO Nadav Kidron to its board to chair a new Str","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL216j4p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNDM","LU2210150020.SGD","IE00BGHQF748.EUR","BK4082","ORMP","LU0314104364.USD","IE00BN0W2V16.EUR","BK4585","IE00BN0W2T93.GBP","BK4546","SG9999014021.USD","BK4007","SG9999014013.SGD","BK4112","NDAQ","BCDF","BK4170","SG9999014039.USD","BK4588","BK4604","IE00BN0W2W23.USD","BK4161","LU2095319765.USD","DRTS","LU2210149790.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LFWD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660482251","title":"Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2660482251","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660482251?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:00","pubTimestamp":1786968002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nTUA1CRYFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ORMP","BK4007","BK4082","DRTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658080952","title":"Oramed Pharmaceuticals Inc Expected to Post Earnings of 43 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658080952","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658080952?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:58","pubTimestamp":1786399084,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc <ORMP.OQ> expected to post earnings of43cents a share - Earnings PreviewOramed Pharmaceuticals IncORMP.OQORMP.Ois expected to  show no change in quarterly revenue when it reports  results on August 12  for the period ending June 30 2026LSEG's mean analyst estimate for Oramed Pharmaceuticals Inc is for earnings of 43 cents per share.Wall Street's median 12-month price target for Oramed Pharmaceuticals Inc is $6.25, about 45.3% above its last closing price of $4.30This summary was machine generated August 10 at 21:58 GMT.  All figures in US dollars unless otherwise stated.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N44725S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658595218","title":"Oramed Swings to Q2 FY26 Net Income of $78.16 Million; Operating Loss Widens 11% to $2.77 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658595218","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658595218?lang=en_us&edition=fundamental","pubTime":"2026-08-11 05:30","pubTimestamp":1786397459,"startTime":"0","endTime":"0","summary":"Oramed swings to Q2 FY26 net income of $78.16 million; operating loss widens 11% to $2.77 millionOramed posted net income of USD 78.16 million, equal to USD 1.84 per diluted share, for the three month","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDLbM0q1j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4170","BK4161","NNDM","BK4007","ORMP","BK4546"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656016933","title":"Oramed Pharmaceuticals Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2656016933","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656016933?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:07","pubTimestamp":1785787669,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals announces annual shareholder meetingOramed will hold its 2026 annual stockholders meeting in Jerusalem on Sept. 15, 2026.Vote scheduled on electing six directors, including Nada","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL2nsflc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ORMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653822277","title":"AlTi Global Leads Our Selection Of 3 Promising Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2653822277","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653822277?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:05","pubTimestamp":1784631906,"startTime":"0","endTime":"0","summary":"Over the last 7 days, the United States market has dropped 1.4%, though it remains up 17% over the past year with earnings forecast to grow by 18% annually. Investing in penny stocks, a term that may seem outdated but still holds relevance, can offer unique growth opportunities typically found in smaller or newer companies. By focusing on those with strong financial health and solid fundamentals, investors might uncover hidden gems that align well with current market conditions.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-cers/cerus/news/alti-global-leads-our-selection-of-3-promising-penny-stocks","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-cers/cerus/news/alti-global-leads-our-selection-of-3-promising-penny-stocks","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4135","BK4007","BK4198","ORMP","ALTI","CERS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648635502","title":"Oramed CFO Avraham Gabay Sells 73,360 Shares for $330,646.76","url":"https://stock-news.laohu8.com/highlight/detail?id=2648635502","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648635502?lang=en_us&edition=fundamental","pubTime":"2026-07-03 05:01","pubTimestamp":1783026086,"startTime":"0","endTime":"0","summary":"Oramed CFO Avraham Gabay sells 73,360 shares for $330,646.76Oramed Pharmaceuticals CFO Avraham Gabay sold 73,360 common shares on July 1.Shares were sold at a weighted average price of $4.51.Gabay’s d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDLc6nmP1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oramed CFO Avraham Gabay Sells 73,360 Shares for $330,646.76","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ORMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648564525","title":"Oramed Amends Bylaws to Streamline Written-consent Record Date, Delivery Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2648564525","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648564525?lang=en_us&edition=fundamental","pubTime":"2026-07-01 04:19","pubTimestamp":1782850799,"startTime":"0","endTime":"0","summary":"Oramed amends bylaws to streamline written-consent record date, delivery rulesOramed adopted Fifth Amended and Restated Bylaws, effective June 25, 2026.Changes reset the record-date framework for stoc","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL1F6Rzl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ORMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644539749","title":"Oramed to join Russell 2000 and 3000 indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=2644539749","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644539749?lang=en_us&edition=fundamental","pubTime":"2026-06-17 21:00","pubTimestamp":1781701211,"startTime":"0","endTime":"0","summary":"Oramed (ORMP) Pharmaceuticals announced that it is set to join the U.S. small cap Russell 2000 and broad-market Russell 3000 Index at the conclusio...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/oramed-to-join-russell-2000-and-3000-indexes-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/oramed-to-join-russell-2000-and-3000-indexes-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635056532","title":"Oramed Pharmaceuticals Delays Quarterly SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635056532","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635056532?lang=en_us&edition=fundamental","pubTime":"2026-05-16 07:34","pubTimestamp":1778888049,"startTime":"0","endTime":"0","summary":"Oramed Pharm ( ($ORMP) ) has released a notification of late filing. Oramed Pharmaceuticals Inc. has filed a Form 12b-25, notifying investors of a ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/oramed-pharmaceuticals-delays-quarterly-sec-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/oramed-pharmaceuticals-delays-quarterly-sec-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635174037","title":"Oramed delays Q1 10-Q filing, cites need to finalize financial statements","url":"https://stock-news.laohu8.com/highlight/detail?id=2635174037","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635174037?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:10","pubTimestamp":1778875831,"startTime":"0","endTime":"0","summary":"Oramed filed a late notice for its quarterly report for period ended March 31, 2026, citing need for more time to complete and finalize financial statements.Form 10-Q expected to be filed on or before fifth calendar day after prescribed due date.Late notice indicated no anticipated significant change in results of operations versus corresponding prior-year period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDLmyQ48:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635729065","title":"Lifeward files initial beneficial ownership statement for Oramed Pharmaceuticals stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2635729065","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635729065?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:20","pubTimestamp":1778793609,"startTime":"0","endTime":"0","summary":"Lifeward Ltd. Form 3 filing shows Oramed Pharmaceuticals as a 10% owner, reporting event date March 25, 2026.Additional exposure through derivative positions tied to ordinary shares, including 1,006,113 pre-funded warrants at USD 0 exercise price.Warrants for 1,296,296 ordinary shares at USD 5.4, warrants for 1,666,666 ordinary shares at USD 5.4, senior secured convertible notes convertible into 1,666,666 ordinary shares at USD 5.4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 14, 2026, and is solely responsible for the i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLHZBMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFWD","ORMP","BK4604","BK4082","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635789270","title":"Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2635789270","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635789270?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:05","pubTimestamp":1778670322,"startTime":"0","endTime":"0","summary":"The market has climbed 1.5% in the last 7 days and is up 26% over the last 12 months, with earnings forecast to grow by 17% annually. While the term 'penny stock' might seem outdated, these investments still offer potential value by focusing on smaller or newer companies with strong financials. In this article, we explore three penny stocks that demonstrate financial strength and could present opportunities for investors seeking hidden value in quality companies.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice1-main-header/1585186659638"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-tmci/treace-medical-concepts/news/spotlight-on-oramed-pharmaceuticals-and-two-other-prominent","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-tmci/treace-medical-concepts/news/spotlight-on-oramed-pharmaceuticals-and-two-other-prominent","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["VFF","LU0049112450.USD","BK4007","III","BABB","MGNX","BK4139","BK4134","BK4209","LX","BK4531","TMCI","BK4189","BK4161","BK4509","CRCT","WDH","NAGE","ORMP","BK4173","BK4579","BK4191","ZJK","BK4166","BK4539","LU1046422090.SGD","BK4121","BK4183","LU1235295612.USD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624530347","title":"Oramed completes Oratech sale to Lifeward for shares, warrants, revenue-sharing payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2624530347","media":"Reuters","labels":["corporation","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624530347?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:22","pubTimestamp":1774988568,"startTime":"0","endTime":"0","summary":"Oramed completed sale of wholly owned unit Oratech Pharma to Lifeward on March 25, 2026.Transaction includes ongoing revenue-sharing payments set at 4% of net revenue from Lifeward ReWalk Personal Exoskeleton products and related extended warranties.Revenue-sharing term runs up to 10 years, subject to earlier cutoff tied to a maximum payment amount or Lifeward reaching $200 million market capitalization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information co","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL7nmf26:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFWD","BK4082","ORMP","BK4007","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622914618","title":"Oramed FY2025 profit rises to $64.0 million; revenue climbs to $2.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622914618","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622914618?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:16","pubTimestamp":1774559766,"startTime":"0","endTime":"0","summary":"Oramed published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025, reporting revenue of USD 2.0 million.Net income was USD 64.02 million, while net income attributable to stockholders was USD 64.05 million.Research and development expense fell 1% to USD 6.38 million, driven by lower raw materials costs partly offset by higher CRO expenses.General and administrative expense rose 35% to USD 8.72 million, mainly due to higher stock-based compensation and professional fees.Oramed said it ended 2025 with USD 45.95 million in cash and cash equivalents and expects its current cash resources to fund planned activities for at least the next 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals In","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL43TdgB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORMP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004431","title":"Lifeward closes strategic partnership with Oramed; access to capital grows to $47 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004431","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004431?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:12","pubTimestamp":1774469547,"startTime":"0","endTime":"0","summary":"Lifeward closed a strategic partnership agreement with Oramed.Under the arrangement, Lifeward acquired Oramed’s clinical-stage Protein Oral Delivery  technology.The partnership provides Lifeward access to up to USD 47 million of capital from Oramed and certain investors.Lifeward accessed USD 10 million of that capital at the closing.The company also made changes to its board of directors in connection with the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief on March 25, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL3znJfR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LFWD","BK4604","ORMP","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622004196","title":"Lifeward Successfully Closes on Strategic Partnership With Oramed","url":"https://stock-news.laohu8.com/highlight/detail?id=2622004196","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622004196?lang=en_us&edition=fundamental","pubTime":"2026-03-26 04:10","pubTimestamp":1774469400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nTUA1B380:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621465081","title":"Oramed Pharmaceuticals Inc  expected to post breakeven results a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621465081","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621465081?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:05","pubTimestamp":1774296307,"startTime":"0","endTime":"0","summary":"Oramed Pharmaceuticals Inc  expected to post breakeven results a share - Earnings Preview Oramed Pharmaceuticals Inc ORMP.OQ ORMP.O is expected to  show no change in quarterly revenue when it reports ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nL8N40B2BE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ORMP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619919428","title":"Lifeward to partner with Oramed in deal providing access to up to USD 47 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2619919428","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619919428?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:05","pubTimestamp":1773403523,"startTime":"0","endTime":"0","summary":"Lifeward shareholders approved the issuance of ordinary shares tied to a strategic partnership with Oramed. Under the agreement, Lifeward will integrate Oramed’s POD oral delivery technology, and Oramed will obtain a significant equity interest through ordinary shares and prefunded warrants. The investment structure provides Lifeward potential access to up to 47 million of capital through equity, convertible notes, milestone-based funding, and warrant coverage. Oramed is expected to manage and fund the POD platform’s clinical development under a clinical trial management agreement to be entered into at closing. The transaction is expected to close after customary closing conditions are satisfied.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL8ynpzS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFWD","BK4082","BK4007","ORMP","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619948194","title":"Lifeward Receives Shareholder Approval to Close on Strategic Partnership With Oramed—Creating Diversified Biomedical Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2619948194","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619948194?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:00","pubTimestamp":1773403202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nTUA95PNHY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ORMP"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.oramed.com","stockEarnings":[{"period":"1week","weight":0.0419},{"period":"1month","weight":0.1034},{"period":"3month","weight":-0.0345},{"period":"6month","weight":0.3785},{"period":"1year","weight":1.1132},{"period":"ytd","weight":0.5719}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.615385,"avgChangeRate":0.018109},{"month":2,"riseRate":0.538462,"avgChangeRate":-0.018104},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.012814},{"month":4,"riseRate":0.785714,"avgChangeRate":0.026126},{"month":5,"riseRate":0.571429,"avgChangeRate":0.04024},{"month":6,"riseRate":0.428571,"avgChangeRate":0.032553},{"month":7,"riseRate":0.428571,"avgChangeRate":0.030434},{"month":8,"riseRate":0.428571,"avgChangeRate":0.014939},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.048853},{"month":10,"riseRate":0.307692,"avgChangeRate":-0.028699},{"month":11,"riseRate":0.538462,"avgChangeRate":0.137309},{"month":12,"riseRate":0.384615,"avgChangeRate":0.051334}],"exchange":"NASDAQ","name":"Oramed Pharmaceuticals","nameEN":"Oramed Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Oramed Pharmaceuticals(ORMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Oramed Pharmaceuticals,ORMP,Oramed Pharmaceuticals股票,Oramed Pharmaceuticals股票老虎,Oramed Pharmaceuticals股票老虎国际,Oramed Pharmaceuticals行情,Oramed Pharmaceuticals股票行情,Oramed Pharmaceuticals股价,Oramed Pharmaceuticals股市,Oramed Pharmaceuticals股票价格,Oramed Pharmaceuticals股票交易,Oramed Pharmaceuticals股票购买,Oramed Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Oramed Pharmaceuticals(ORMP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Oramed Pharmaceuticals(ORMP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction